East Rutherford, NJ – February 19, 2021 – Cambrex today announced that it had been recognized across six categories in the annual CMO (Contract Manufacturing Organization) Leadership Awards.
Cambrex has now received CMO awards for seven consecutive years, and this year, has been recognized in the following categories: Capabilities (Overall, Small Pharma), Compatibility (Overall, Small Pharma), Expertise (Overall, Small Pharma), Quality (Overall, Small Pharma), Reliability (Small Pharma), and Service (Overall, Small Pharma).
“Once again, Cambrex is honored to be recognized by our customers and industry peers as a leading supplier to the pharmaceutical industry”, commented Tom Loewald, Chief Executive Officer at Cambrex. He added, “Demand for small molecule manufacturing constantly grows and evolves, and we are committed to investing in the capacity, capabilities and expertise to further strengthen our position as a market-leading CDMO delivering customized, customer-centric solutions.”
Louis Garguilo, Chief Editor and Conference Chair, Outsourced Pharma, added, “Congratulations to all the 2021 CMO Leadership Award winners; you keep the biopharma industry moving forward. An award in any category – capabilities, compatibility, expertise, quality, reliability and service – acknowledges your advanced leadership and effective execution and that rare flexibility to serve all customers through even the most difficult of times.”
In 2019, Cambrex was acquired by funds advised by Permira, a global investment firm, to continue to build upon Cambrex’s market leading position in API development and manufacturing and support the growth of its end-to-end integrated service offerings across the pharmaceutical value chain.
Established in 2011, the CMO Leadership Awards recognize top outsourcing partners, determined by feedback from sponsor companies who outsource manufacturing. The awards are presented by Outsourced Pharma, Life Science Leader magazine and Industry Standard Research.